当前位置： SCI文献检索 > DRUG SAFETY期刊下所有文献 > Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

Abstract：

BACKGROUND AND OBJECTIVE:Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or 'statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitoring. METHODS:An observational cohort study in which patients were identified from dispensed prescriptions issued by primary care physicians/general practitioners (GPs) between August and December 2003. Demographic and clinical-event data were collected from questionnaires posted to GPs at least 6 months after the date of first prescription for each patient. Stratified analysis of specific events by starting dose of rosuvastatin was conducted. Follow-up and causality assessment of medically significant events was undertaken. RESULTS:The cohort comprised 11,680 patients (median age 64 years); 50.3% were males (5880 of 11,680). The median period of treatment was 9.8 months. Of these patients, 72.7% (n = 8494) were started on rosuvastatin 10 mg/day. A total of 17.5% (n = 2047) of the patients were reported to have stopped treatment with rosuvastatin. Myalgia was the most frequent reason for stopping rosuvastatin and the most frequently reported clinical event. A 2.5-fold increase in the rate of abnormal liver-function tests (LFTs) was observed for patients started on rosuvastatin 40 mg/day compared with those started on 10 mg/day (2.71; 95% CI 1.53, 4.53). No case of rhabdomyolysis was reported in this cohort. CONCLUSION:Rosuvastatin was considered to be a reasonably well tolerated drug. In the majority of patients, rosuvastatin was prescribed in line with recommendations. Abnormality of LFTs was found to be more frequent with the 40 mg/day dosage of rosuvastatin. Results from this study should be taken into account together with those of other clinical and pharmacoepidemiological studies of rosuvastatin.

journal_name

Drug Saf

journal_title

Drug safety

authors

Kasliwal R,Wilton LV,Cornelius V,Aurich-Barrera B,Shakir SA

doi

10.2165/00002018-200730020-00005

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

157-70

issue

2

eissn

0114-5916

issn

1179-1942

pii

3025

journal_volume

30

pub_type

杂志文章

相关文献

DRUG SAFETY文献大全
  • A benefit-risk assessment of misoprostol for cervical ripening and labour induction.

    abstract：:Misoprostol, a prostaglandin E(1) analogue, is widely used in the US and other countries for cervical ripening and labour induction. Its use for these indications is not approved by the US Food and Drug Administration (FDA). The manufacturer of misoprostol issued a letter to American healthcare providers in August 200...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200225090-00005

    authors： Wing DA

    更新日期：2002-01-01 00:00:00

  • Drug treatment of depression in HIV-positive patients : safety considerations.

    abstract：:Safe and effective treatment of major depression, one of the most common comorbid conditions in individuals infected with HIV, significantly lowers morbidity and mortality from HIV disease. However, optimal treatment of both conditions is complicated by interactions between the disease processes as well as the pharmac...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200528090-00002

    authors： Pieper AA,Treisman GJ

    更新日期：2005-01-01 00:00:00

  • Paraquat poisoning. An overview of the current status.

    abstract：:Paraquat is a bipyridyl compound with no known chronic toxicity or teratogenicity. It is poorly absorbed when inhaled, but causes severe illness when ingested orally, death usually occurring within 2 days of ingestion of 50 mg/kg. At lower doses death may be delayed for several weeks. The toxic compound accumulates in...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-199005040-00002

    authors： Bismuth C,Garnier R,Baud FJ,Muszynski J,Keyes C

    更新日期：1990-07-01 00:00:00

  • Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.

    abstract：BACKGROUND:Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin's lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions ...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/11585960-000000000-00000

    authors： Brown BA,Torabi M

    更新日期：2011-02-01 00:00:00

  • Measles vaccination and inflammatory bowel disease: controversy laid to rest?

    abstract：:The increasing incidence of Crohn's disease has lead to speculation about changes in exposures to environmental or infectious agents. Considerable attention has focused on the role of measles infection and/or vaccination in the pathogenesis of Crohn's disease and ulcerative colitis. Current evidence regarding the asso...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200124130-00001

    authors： Davis RL,Bohlke K

    更新日期：2001-01-01 00:00:00

  • Association between leukotriene-modifying agents and suicide: what is the evidence?

    abstract：:The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LT...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/11587260-000000000-00000

    authors： Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

    更新日期：2011-07-01 00:00:00

  • Use of herbal medicines by patients receiving warfarin.

    abstract：BACKGROUND:Patients receiving warfarin therapy are discouraged from taking herbal medicines. Whether patients adhere to this advice and, if they do not, the types of products they use, are not known. OBJECTIVE:The objective of this observational study was to estimate the magnitude of use of herbal medicines among Chin...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/00002018-200326080-00004

    authors： Wong RS,Cheng G,Chan TY

    更新日期：2003-01-01 00:00:00

  • Betahistine: a retrospective synopsis of safety data.

    abstract：:Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière's disease and the symptomatic treatment of vertigo. It is estimated from sales information that >130 million patients have been exposed to the drug since its registration in 1968. In this revi...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/00002018-200629110-00004

    authors： Jeck-Thole S,Wagner W

    更新日期：2006-01-01 00:00:00

  • PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.

    abstract：INTRODUCTION:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is) were associated with a risk of neurocognitive adverse drug reactions (ADRs). OBJECTIVE:We aimed to investigate the occurrence of neuropsychiatric ADRs related to PCSK9Is. METHODS:We analyzed Individual Case Safety Reports (ICSRs) sent thr...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.1007/s40264-020-01021-3

    authors： di Mauro G,Zinzi A,Scavone C,Mascolo A,Gaio M,Sportiello L,Ferrajolo C,Rafaniello C,Rossi F,Capuano A

    更新日期：2020-12-22 00:00:00

  • Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

    abstract：INTRODUCTION:Pharmacovigilance includes analysis of large databases of information on drugs and events using algorithms that detect disproportional frequencies of associations. In order to test such algorithms, attempts have been made to provide canonical reference lists of so-called 'positive controls' and 'negative c...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.1007/s40264-016-0392-2

    authors： Hauben M,Aronson JK,Ferner RE

    更新日期：2016-05-01 00:00:00

  • Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.

    abstract：:Randomized controlled trials always report the dose assessed and usually include a measure of adherence. By comparison, observational studies assessing medication safety often fail to report the dose used and rarely report any measure of adherence to therapy. This limits the ability to control for differences in doses...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.1007/s40264-015-0347-z

    authors： Roughead EE,Pratt NL

    更新日期：2015-12-01 00:00:00

  • Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting.

    abstract：BACKGROUND:Fatal venous thromboembolism (VTE) is a rare complication of combined oral contraceptive (COC) treatment. This study aims to determine incidences of fatal VTE in relation to the type of COC and the percentage of cases reported to the Swedish Adverse Drug Reactions Advisory Committee (SADRAC). A further aim i...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/00002018-200528100-00007

    authors： Hedenmalm K,Samuelsson E

    更新日期：2005-01-01 00:00:00

  • Improving safety reporting from randomised trials.

    abstract：:Randomised clinical trials offer a unique opportunity for capturing safety information under a controlled setting that minimises biases in the comparison of different therapeutic options. Nevertheless, empirical evidence across diverse medical fields suggests that the reporting of safety information in clinical trials...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200225020-00002

    authors： Ioannidis JP,Lau J

    更新日期：2002-01-01 00:00:00

  • Clinical-pharmacological strategies to assess drug interaction potential during drug development.

    abstract：:Drug interactions in patients receiving multiple drug regimens are a constant concern for the clinician. With the increased availability of new drugs and their concomitant use with other drugs, there has been a rise in the potential for adverse drug interactions as demonstrated by the recent withdrawals of newly marke...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200124100-00001

    authors： Kuhlmann J,Mück W

    更新日期：2001-01-01 00:00:00

  • Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

    abstract：BACKGROUND:Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signal...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/11594770-000000000-00000

    authors： Wahl PM,Gagne JJ,Wasser TE,Eisenberg DF,Rodgers JK,Daniel GW,Wilson M,Schneeweiss S,Rassen JA,Patrick AR,Avorn J,Bohn RL

    更新日期：2012-05-01 00:00:00

  • Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

    abstract：:Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic effects on...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.1007/s40264-013-0050-x

    authors： Shah DR,Shah RR,Morganroth J

    更新日期：2013-06-01 00:00:00

  • Propofol infusion syndrome: an overview of a perplexing disease.

    abstract：:Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent that is widely used in adults and children for sedation and the induction and maintenance of anaesthesia. Propofol has gained popularity for its rapid onset and rapid recovery even after prolonged use, and for the neuroprotection conferred. Howev...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200831040-00003

    authors： Fodale V,La Monaca E

    更新日期：2008-01-01 00:00:00

  • Non-medicinal ingredients.

    abstract：:Many drug products contain excipients which perform important functions in terms of stability, solubility and identification. Excipients should not be considered as inactive ingredients, as they have been associated with a wide range of adverse reactions in some individuals. Monitoring for excipient toxicity is import...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-199000051-00015

    authors： Scott AW

    更新日期：1990-01-01 00:00:00

  • All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

    abstract：INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk ...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.1007/s40264-018-00786-y

    authors： Jeong S,Tchoe HJ,Li J,Shin JY

    更新日期：2019-06-01 00:00:00

  • Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

    abstract：BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...

    journal_title：Drug safety

    pub_type： 杂志文章,meta分析,评审

    doi：10.2165/11598050-000000000-00000

    authors： Manzoli L,De Vito C,Marzuillo C,Boccia A,Villari P

    更新日期：2012-03-01 00:00:00

  • Treatment with Selective Serotonin Reuptake Inhibitors in the Third Trimester of Pregnancy : Effects on the Infant.

    abstract：:Pharmacotherapy in pregnant women is often necessary to treat chronic or relapsing depression or anxiety disorders. Studies that have evaluated the safety of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy have not shown an enhanced risk of major congenital malformations and these results may have c...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200528070-00002

    authors： Nordeng H,Spigset O

    更新日期：2005-07-01 00:00:00

  • A risk-benefit assessment of HIV protease inhibitors.

    abstract：:The use of triple regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international guidelines. The widespread availabilit...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-199920040-00002

    authors： Moyle GJ,Gazzard BG

    更新日期：1999-04-01 00:00:00

  • Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

    abstract：INTRODUCTION:The case-population approach compares exposure among cases to that of their source population. By using aggregated data to estimate the denominator, this approach can provide a real-time estimate of an association that could be particularly valuable to explore urgent vaccine safety concerns and to generate...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.1007/s40264-016-0449-2

    authors： Théophile H,Moore N,Robinson P,Bégaud B,Pariente A

    更新日期：2016-12-01 00:00:00

  • Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports.

    abstract：BACKGROUND:Eosinophilic pneumonia (EP) has been noted in association with daptomycin use. The product labelling was recently updated to include EP in the Warnings and Precautions and Post-Marketing Experience sections. OBJECTIVE:The objective of this study was to analyse adverse event (AE) reports submitted to the US ...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/11597460-000000000-00000

    authors： Kim PW,Sorbello AF,Wassel RT,Pham TM,Tonning JM,Nambiar S

    更新日期：2012-06-01 00:00:00

  • Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

    abstract：BACKGROUND:Following reports of sudden death in patients taking medication to treat attention-deficit hyperactivity disorder (ADHD), this study aimed to identify cases of death in patients prescribed stimulants and atomoxetine and to determine any association between these and sudden death. METHOD:The UK General Pract...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/11317630-000000000-00000

    authors： McCarthy S,Cranswick N,Potts L,Taylor E,Wong IC

    更新日期：2009-01-01 00:00:00

  • What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

    abstract：:In the US, adverse drug reactions (ADRs) rank between the fourth to sixth leading cause of death, ahead of pneumonia and diabetes mellitus. An important reason for the high incidence of serious and fatal ADRs is that the existing drug development paradigms do not generate adequate information on the mechanistic source...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/00002018-200124020-00001

    authors： Ozdemir V,Shear NH,Kalow W

    更新日期：2001-01-01 00:00:00

  • The Effect of Positively Framing Side-Effect Risk in Two Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A Randomised Trial of 16- to 75-Year-Olds in England.

    abstract：INTRODUCTION:Reframing side-effect information in patient information leaflets (PILs) in terms of those who remain side-effect-free may reduce negative expectations and side-effects, although there are concerns this may impact informed consent. This study compared two versions of positively framed PILs with current pra...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.1007/s40264-020-00959-8

    authors： Webster RK,Rubin GJ

    更新日期：2020-10-01 00:00:00

  • Discourse on safe drug use: symbolic logics and ethical aspects.

    abstract：:Drug safety is not a matter for healthcare professionals alone. Patients are also involved, at three different levels: (i) in the behaviours patients adopt to reduce the adverse effects of the drugs; (ii) in regard to what some doctors say to their patients about drug risks; and (iii) in what the pharmaceutical indust...

    journal_title：Drug safety

    pub_type： 杂志文章,评审

    doi：10.2165/11538320-000000000-00000

    authors： Fainzang S

    更新日期：2010-08-01 00:00:00

  • Benzodiazepine Use and Risk of Acute Angle-Closure Glaucoma: A Population-Based Case-Crossover Study.

    abstract：INTRODUCTION:Theoretically, benzodiazepines (BZDs) can narrow the iridocorneal angle and induce acute angle-closure glaucoma (AACG). However, little evidence exists regarding this association. OBJECTIVE:The objective of this study was to assess whether the use of BZDs is associated with the risk of AACG. METHODS:We c...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.1007/s40264-020-00914-7

    authors： Kim WJ,Li J,Oh IS,Song I,Lee E,Namkoong K,Shin JY

    更新日期：2020-06-01 00:00:00

  • Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.

    abstract：BACKGROUND:Over-the-counter analgesics (OTCAs), principally paracetamol (acetaminophen)-containing compounds and NSAIDs, are commonly used medications. Guidelines for the use of these agents in patients with chronic liver disease (CLD) are not available, despite the possibility that such patients may be more susceptibl...

    journal_title：Drug safety

    pub_type： 杂志文章

    doi：10.2165/00002018-200831030-00007

    authors： Rossi S,Assis DN,Awsare M,Brunner M,Skole K,Rai J,Andrel J,Herrine SK,Reddy RK,Navarro VJ

    更新日期：2008-01-01 00:00:00